NASDAQ: VRCA - Verrica Pharmaceuticals Inc.

छह महीने के लिए लाभप्रदता: -71.57%
भाग प्रतिफल: 0.00%
सेक्टर: Healthcare

पदोन्नति कार्यक्रम Verrica Pharmaceuticals Inc.

उन्नत शेड्यूल सरल ग्राफ
Financial Markets by TradingView

कंपनी के बारे में Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts.

अधिक जानकारी
It is also developing VP-315, an oncolytic peptide-based injectable therapy for the treatment of dermatology oncologic conditions, including basal cell carcinoma; and cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
तुलना सूची में जोड़ें
घड़ी सूची में जोड़ें
पोर्टफोलियो में जोड़ें
मूल्य सूचना जोड़ें

IPO date 2018-06-15
ISIN US92511W1080
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.verrica.com
Цена ао 0.591
प्रति दिन मूल्य परिवर्तन: -9.09% (0.591)
प्रति सप्ताह मूल्य परिवर्तन: -11.63% (0.608)
प्रति माह मूल्य परिवर्तन: -17.34% (0.65)
3 महीने में कीमत में बदलाव: -29.4% (0.761)
छह महीने में कीमत में बदलाव: -71.57% (1.89)
प्रति वर्ष मूल्य परिवर्तन: -89.03% (4.9)
3 वर्षों में मूल्य परिवर्तन: -93.28% (7.99)
5 वर्षों में मूल्य परिवर्तन: -96.39% (14.9)
10 वर्षों में मूल्य परिवर्तन: 0% (0.5373)
वर्ष की शुरुआत से मूल्य परिवर्तन: -22.58% (0.694)
सभी पैरामीटर

बहुत मूल्यवान समझना

नाम अर्थ श्रेणी
P/S 57.52 1
P/BV 14.91 1
P/E 0 0
EV/EBITDA -4.34 0
कुल: 2.75

क्षमता

नाम अर्थ श्रेणी
ROA, % -82.1 0
ROE, % -338.99 0
कुल: 0

लाभांश

नाम अर्थ श्रेणी
Div yield, % 0 0
DSI 0 0
कुल: 0

कर्तव्य

नाम अर्थ श्रेणी
Debt/EBITDA -0.6985 10
कुल: 7.8

विकास का आवेग

नाम अर्थ श्रेणी
लाभप्रदता Revenue, % -57.3 0
लाभप्रदता Ebitda, % 106.63 10
लाभप्रदता EPS, % 40.72 6
कुल: 6.2
अधिक जानकारी

संस्थानों आयतन शेयर करना, %
Perceptive Advisors LLC 5038983 11.98
Avoro Capital Advisors LLC 2954064 7.02
FMR, LLC 1504716 3.58
Vanguard Group Inc 1226858 2.92
Blackrock Inc. 1051050 2.5
Geode Capital Management, LLC 416790 0.99
State Street Corporation 382743 0.91
Caligan Partners, LP 259593 0.62
Northern Trust Corporation 187478 0.45
Boxer Capital, LLC 166955 0.4

ETF शेयर करना, % वर्ष के लिए लाभप्रदता, % लाभांश, %
Invesco Dorsey Wright SmallCap Momentum ETF 0.07518 33.91 0.61241
iShares Micro-Cap ETF 0.00867 17.09 1.54048
iShares Russell 2000 Growth ETF 0.0017 38.04 0.6026
ProShares UltraPro Russell2000 0.00074 89.82 1.47873
ProShares Hedge Replication ETF 0.00022 5.92 1.47892
Vanguard Russell 2000 Growth ETF 0 23.05 0.60264
Vanguard Russell 2000 ETF 0 17.16 1.48801
Vanguard Russell 3000 ETF 0 31.87 1.43817



पर्यवेक्षक नौकरी का शीर्षक भुगतान जन्म का साल
Mr. Ted White President, CEO & Director 772.77k 1965 (60 साल)
Dr. Gary Goldenberg M.D. Chief Medical Officer 553.03k 1977 (48 साल)
Mr. P. Terence Kohler Chief Financial Officer N/A
Mr. Christopher G. Hayes Chief Legal Officer, Secretary, Chief Compliance Officer & General Counsel N/A 1964 (61 वर्ष)
Mr. Eugene Scavola Executive Vice President of Technical Operations N/A
Dr. Bradley J. Catalone MBA, Ph.D. Head of Drug Development N/A

पता: United States, West Chester. PA, 44 West Gay Street - Google मानचित्र में खोलें, यांडेक्स मानचित्र खोलें
वेबसाइट: https://www.verrica.com